This book is dedicated to all those with

Pref ace
The Marfan Trust has become increasingly active over the past few years. Our support network has grown and we have engaged with many more people through events and fundraising activities. Our website and social media are becoming central in explaining what the charity is doing and how our Marfan patient community and supporters are engaging with us and one another. The Trustees held their strategy meeting early in 2015 to determine the charity's direction and goals over the next few years. The outcome is published on our website. Our three key objectives remain: medical research as a high priority; producing educational literature and raising awareness; and support and guidance provided for our patient community. We are growing as a charity, providing top quality research in our designated laboratory, education, awareness and support in the UK and beyond.
The AIMS (Aortic Irbesartan in Marfan Syndrome) Trial, continuing until 2018, is one of a number of international trials comparing beta-blocker therapy with losartan or irbesartan therapy. This UK trial, co-funded by the Marfan Trust and the British Heart Foundation, is a main priority. With 21 participating Marfan syndrome clinics around the UK, this trial has provided an opportunity for Marfan syndrome patients to have local diagnosis and support. Additional research is undertaken in our laboratory into overlapping syndromes such as ectopia lentis and scoliosis, and translational research, which will ultimately benefi t patients through improved clarifi cation of diagnosis and the utilisation of results to develop resources for medical professionals and education. One example of this is our new paediatric guide, formulated from research incorporated into our children's database. We have provided funding support to recruit a number of medical and bioscience students to undertake research work. This has assisted our resident researchers and also introduced a new generation of future medical and scientifi c professionals to genetics and Marfan syndrome in particular.
Knowledge is everything and the fi rst step to knowledge is awareness. We provide a February Awareness Month over various media platforms. Family Fun Days are held twice yearly and permit families to share problems and solutions. Our updated literature is now available. We are particularly targeting general practitioners in the UK, where there seems to be a lack of awareness and understanding of Marfan syndrome.
This present textbook has been eagerly awaited. 
Rare or Common?
Marfan syndrome is generally thought to be rare, but clinicians who have seen how the gene expression can shade into normality in affected members of a family, suspect that its overall frequency could be underestimated, as a recent collaborative publication states [ 1 ] . The fact that the syndrome presents in many different ways may also hinder its recognition. Marfan syndrome patients may fi rst be referred to any one of a number of specialists. Each doctor is likely to be familiar with a particular aspect of the syndrome, but less familiar with its other features. The aim of this guide is to pool the knowledge available from different experienced specialists, and to make it available to the many clinicians likely to encounter a patient with this condition.
Co-ordinated Care
Who should care for the Marfan syndrome patient? I believe the answer is that we should all do so. Whoever fi rst suspects the diagnosis should pursue the question until it is either proved or disproved, and should consider what other specialist opinions might be required. All patients should be referred for genetic counselling, both to help with diagnosis, and to identify other affected family members, as well as provide guidance about the risk to future children. Each patient is best cared for by a team, led by one co-ordinating physician who is familiar with all aspects of the condition. This is likely to be a geneticist or cardiologist. The rise of aortopathy diagnostic and follow-up clinics is to be applauded. As a result, patients can be referred locally rather than having to travel long distances for management.
International Collaboration and Patient Support
National and international patient support group networks have been set up, and active research is being undertaken into the cause, early diagnosis, treatment, and prevention of Marfan syndrome. A summary of diagnosis and management is provided in Chap. 2 , Table 2 .2. Subsequent chapters show that the management of this condition can be much improved by wider knowledge of its principal features, most of which can now be effectively treated, resulting in more normal lifespan [ 2 ] . The discovery that the underlying connective tissue defect in Marfan syndrome results from a primary defi ciency of fi brillin-1 has led to attempts at more fundamental methods of prevention and treatment, such as the international trials of losartan and irbesartan aimed at preserving the aortic media [ 3 ] .
First Gene for Familial TAAD
International collaborative groups aimed at discovering new genes and new treatments are proving effective [ 3 ] . Marfan syndrome has led the way in this fi eld of Familial Thoracic Aortic Aneurysm and Dissection (FTAAD), and clinicians experienced in managing this condition will be called upon to manage many similar genetically-determined aneurysms in future [ 4 ] .
Taking the Family History
A three or four generation family history is obtained wherever possible, remembering that 25 % of patients are the result of a new mutation, while 75 % have inherited the condition from one parent or the other. Each patient is asked to bring already existing snapshots of siblings, parents and offspring so that if dominant inheritance is present, it can be tracked through photographs. Operative reports and death certifi cates may have to be obtained. Manifestations of early onset eye, heart or skeletal problems are sought ( 
Physical Examination
Careful examination of the patient for any sign of connective tissue disorder is undertaken. Our examination sheet is shown in Fig. 2.1 . The examination is performed starting from the head down. The joint hypermobility score is that of Beighton [ 1 ] and any value of 5 or greater should be considered abnormal. In addition, small joint hypermobility of fi ngers and toes should be taken into account. This may be racial (Africans, Indians, Arabs, Spaniards) [ 1 , 2 ] and should be discounted if it is racial. Joint contractures should also be noted. Particular attention should be paid to skin, since it contains all of the connective tissue elements found in the aortic wall. Is it thin (anterior chest wall), stretchy (side of neck), or striated, especially in the lumbar area? Horizontal striae in the lumbar area are usually found in Marfan syndrome. Vertical striae on the buttocks suggest joint hypermobility syndrome (Ehlers Danlos Type III).
If the patient is a child, physical examination should be placed in the middle column of the examination form, with father's and mother's examinations placed either side. In this way, common features shared with either parent can be highlighted. Often a tall slim pubertal hypermobile child may simply result from the genetic combination of joint hypermobility from one parent, and tall stature from the other parent, in the presence of a normal echocardiogram in the child. Demonstrating shared features indicates that the child is not affected with a new condition, but simply a new combination of family genes from both sides. But it must be considered that a Marfan syndrome child may be born into a family which has hypermobility.
A differential diagnosis includes many conditions and we must not overdiagnose Marfan syndrome. The commonest condition mistaken for Marfan syndrome is undoubtedly Ehlers Danlos syndrome Type III (joint hypermobility syndrome). Rare conditions include rarely congenital contractural arachodactyly [ 3 ] , and overgrowth syndromes, for example Sotos syndrome [ 4 ] . Another common overlap syndrome is Ectopia Lentis as an isolated problem [ 5 ] . If the echocardiogram is normal, and a parent is affected with dislocated lenses, then this may still be due to mild fi brillin-1 defi ciency, often with a mutation in the fi rst 15 exons of the gene [ 6 ] . If the child with Ectopia Lentis is the only one in the family and parents are related (consanguineous), this is most likely an autosomal recessive type of Ectopia Lentis due to ADAMTSL4, ADAMTS18, or other gene [ 5 ] . Adolescent idiopathic scoliosis can also be inherited dominantly, and is now being shown to be due to separate genes [ 7 ] .
Suspected cases under the age of two should have plasma amino acid analysis in the absence of pyridoxine supplementation to rule out the diagnosis of homocystinuria, since failure to treat may lead to mental retardation [ 8 ]. 
Diagnostic Pathway
The diagnostic features for Marfan syndrome have been presented and updated [ 9 ] . However, this highly detailed classifi cation of fi ndings is diffi cult to remember, and a simple guideline is that the patient must have classical severe fi ndings in two out of three systems (eyes, heart, skeleton) in order to make a clinical diagnosis, or in the presence of a dominant family history, one system involvement. We have created a diagnostic pathway to make the clinical classifi cation easier (Figs. 2.2 and  2. 3 ). For a detailed summary of the minor features considered, please see the revised Ghent criteria [ 10 ].
Fibrillin-1 Mutation Screen
Most importantly, this condition is no longer just a clinical diagnosis. Because it is very variable with reduced penetrance, a mutation screen including MLPA should be performed in any questionable case. The cost of this is fully justifi ed, since other tests such as a scan for dural ectasia, or repeated echocardiograms, very quickly add up to the same sum. Also, the psychological damage of bringing an unaffected patient back on an annual basis for echocardiography must be considered. Such patients can become hypochondriacal through repeated examinations. It is much more professional to do a simple test which will rule out the condition with 97 % accuracy.
Timetable of Care
In Table 2 .2 you will fi nd an overview of management. Table 2 .3 is a timetable of care which could be fi led by the general practitioner in the notes so that the patient is referred for specialist care at key points in their life.
Endocarditis Prophylaxis
Recent summaries of best care for Marfan syndrome patients abound [ 11 -13 ] . One point of difference is whether patients require antibiotic therapy for dental or other minor surgery. Because cases of endocarditis have occurred following dental work, this should be considered as seriously as minor surgery, and the patient covered adequately with antibiotic before treatment and after treatment. Any patient who has had heart surgery should have antibiotic therapy. This is because Marfan syndrome patients have weak connective tissue which cannot resist infection normally. Any bacterial or even viral infection can invade rapidly and may prove life-threatening.
